SNSS News 5.16 Sunesis Pharmaceuticals (SNSS)

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Sunesis Pharmaceuticals (SNSS) 5.16 $SNSS

2 Biotech Stocks to Watch: Merrimack Pharmaceuticals and Sunesis Pharmaceuticals
George Budwell, The Motley Fool - Motley Fool - Thu Apr 10, 5:30PM CDT
Although 2014 has gotten off to a rocky start for biotechs, a fair number of companies have exploded higher after reporting positive clinical trial data. For example, Endocyte doubled in a day after unveiling positive data for its experimental...

Ambit's Oncology Drug in Phase III - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Apr 09, 3:55PM CDT
Ambit Biosciences commenced a phase III study (QUANTUM-R) on its lead oncology candidate, quizartinib for acute myeloid leukemia (AML).

Sunesis Announces Presentation of Positive Results From Ongoing MD Anderson-Sponsored Trial of Vosaroxin in AML and High-Risk MDS
GlobeNewswire - Tue Apr 08, 8:39AM CDT
Data Presented at AACR 2014 Annual Meeting

Is Now the Time to Invest in Agios Pharmaceuticals, Inc?
George Budwell, The Motley Fool - Motley Fool - Mon Apr 07, 10:17AM CDT
Shares of Agios Pharmaceuticals spiked over 20% this morning after the company announced that its early stage blood cancer drug, AG-221, is showing unexpectedly strong efficacy signals. Specifically, six of the seven evaluable patients exhibited...

Sunesis Announces MD Anderson Sponsored Trial of Vosaroxin in AML and High-Risk MDS Poster to be Presented at AACR 2014
GlobeNewswire - Wed Apr 02, 6:00AM CDT
Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced that updated data from the ongoing Phase 1b/2 University of Texas MD Anderson Cancer Center-sponsored trial of vosaroxin in combination with decitabine in older patients with previously untreated acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS) will be presented at the American Association for Cancer Research Annual Meeting 2014 (AACR) in San Diego, California.

Nasdaq stocks posting largest percentage decreases
AP - Fri Mar 28, 5:02PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at the close of trading:

Appointments, Financial Reports, and FDA Approvals - Analyst Notes on Hospira, Karyopharm, Revance, Pluristem, and Sunesis
PR Newswire - Tue Mar 11, 8:19AM CDT
Today, Analysts Review released its analysts' notes regarding Hospira Inc. (NYSE: HSP), Karyopharm Therapeutics, Inc. (NASDAQ: KPTI), Revance Therapeutics, Inc. (NASDAQ: RVNC), Pluristem Therapeutics, Inc. (NASDAQ: PSTI), and Sunesis Pharmaceuticals, Inc. (NASDAQ: SNSS). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register

Sunesis Pharmaceuticals Reports Fourth Quarter and Full-Year 2013 Financial Results and Recent Highlights
GlobeNewswire - Thu Mar 06, 6:09AM CST
Phase 1b/2 Data From MD Anderson Sponsored Study of Vosaroxin in AML and

Sunesis (SNSS) Jumps: Stock Moves 6.8% Higher - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Mar 05, 8:25AM CST
Sunesis was a big mover last session, as the company saw its shares rise nearly 7% on the day.

Sunesis to Present at Upcoming Investor Conferences
GlobeNewswire - Fri Feb 28, 7:18AM CST
Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced that Daniel Swisher, Chief Executive Officer and President of Sunesis, will present at two upcoming investor conferences;

Sunesis to Host Conference Call on March 6th to Discuss Fourth Quarter and Full-Year 2013 Financial Results and Recent Highlights
GlobeNewswire - Fri Feb 28, 7:18AM CST
Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced that it will host a conference call on Thursday, March 6, 2014 at 11:00 a.m. Eastern Time to discuss corporate updates and financial results for the fourth quarter and year ended December 31, 2013.

Sunesis Announces Pricing of a $43.0 Million Public Offering of Common Stock and Warrants
GlobeNewswire - Thu Feb 27, 8:53AM CST
Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced the pricing of an underwritten public offering of 4,650,000 shares of common stock together with two warrants to purchase one share of the company's common stock. The public offering price of each share of common stock and two accompanying warrants was $9.25, resulting in gross proceeds to the company of $43.0 million. Net proceeds are expected to be approximately $40.0 million, after deducting the underwriting discount and estimated offering expenses payable by Sunesis. If exercised in full, the warrants could result in additional net financing proceeds to Sunesis of $95.3 million. The offering is expected to close on or about March 4, 2014, subject to customary closing conditions.

Sunesis Announces Proposed Public Offering of Common Stock and Warrants
GlobeNewswire - Wed Feb 26, 3:14PM CST
Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced that it intends to offer and sell, subject to market and other conditions, shares of its common stock and warrants to purchase shares of its common stock in an underwritten public offering. There can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

3 Small Cap Biotechs Developing Novel Cancer Treatments
George Budwell, The Motley Fool - Motley Fool - Tue Feb 18, 1:30PM CST
Cancer drugs can be game-changers for their developers because of their comparatively high margins and their tendency to be applicable to a broad array of disease states. In short, Foolish investors would be wise to keep an eye out for companies...

Sunesis Pharmaceuticals (SNSS) Falls: Stock Goes Down 5.4% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Feb 11, 7:58AM CST
Sunesis Pharmaceuticals saw a big move last session, as the company’s shares fell by over 5% on the day

Sunesis (SNSS) Catches Eye: Stock Soars 18.3% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Feb 10, 8:25AM CST
Sunesis was a big mover last session, with shares surging over 18%.

Sunesis Appoints Joseph I. DePinto as Chief Commercial Officer, Updates VALOR Timeline to Unblinding of Data
GlobeNewswire - Mon Feb 10, 6:00AM CST
Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced the appointment of Joseph I. DePinto to the newly created position of Executive Vice President and Chief Commercial Officer. Mr. DePinto brings over two decades of experience in global commercial operations, including the leadership of the commercial, marketing and strategic development efforts behind a number of prominent oncology products.
Scroll down for more posts ▼

Top 10 Most Recent News Articles

MFB Bancorp Offering Puts Chicago Bank Conversion First

Updated Category News Views 70

A small Chicago thrift is asking investors to fund a corporate makeover, and the fine print matters more than the $10 sticker price. MFB Bancorp has commenced an offering tied to the planned conversion of Mutual Federal Bancorp, MHC from a mutual holding company structure into a stock holding company. This is not some high-growth bank story with a shiny new branch map. It...

Continue Reading
Goosehead Restatement Puts Accounting Trust on Trial

Updated Category News Views 116

A filing delay can be irritating; a multi-year no-rely warning is something uglier. Goosehead Insurance told investors on November 9, 2026, that it would not timely file its quarterly report for the period ended September 30 and that prior financial statements must be restated. That is not a garden-variety paperwork hiccup. It reaches back across fiscal 2023, 2024 and...

Continue Reading
Sinopec's Green Fuel Push Meets a Hard Reality Check

Updated Category News Views 174

A refinery giant talking about green jet fuel at a climate summit is exactly the sort of thing that makes old energy hands squint first—and then check the asset list. Sinopec did bring more than lofty language to its Nov. 16 COP31 side event in Antalya: it brought long-range energy forecasts, named fuel-production routes, hydrogen infrastructure and operating projects....

Continue Reading
ATRenew's Q3 Profit Jump Meets a Cash Balance Test

Updated Category News Views 105

Used phones do not make for glamorous investing, but this quarter has some real muscle behind it. ATRenew turned a 25.3% revenue gain into a 57.9% jump in operating income for the three months ended September 30, and that is the sort of operating leverage I want to see before getting carried away with a circular-economy story. Margins Finally Move in the Right Direction...

Continue Reading
SQM Investigation Puts Chile Approval Claims on Trial

Updated Category News Views 9

A Regulatory Promise Meets a Rough Earnings Reaction A 5.52% haircut after disappointing quarterly numbers is the sort of thing that makes shareholders stop pretending every loose management comment is harmless. Sociedad Química y Minera de Chile, NYSE:SQM, is facing an investigation by Levi & Korsinsky into public statements concerning regulatory matters, particularly...

Continue Reading
&honey's U.S. Beauty Awards Sweep Puts Distribution in Focus

Updated Category News Views 128

Three glossy-magazine nods may sound fluffy, but shelf momentum is never entirely fluff. Japanese haircare brand &honey says its Deep Moist Shampoo, Treatment and Hair Oil each landed 2026 recognition from Marie Claire, ELLE and Allure. For a consumer brand trying to make an American habit out of a Japanese haircare ritual, that is the sort of validation worth...

Continue Reading
T. Rowe Price Expands Teams Across 12 Fund Strategies

Updated Category News Views 73

A Quiet Personnel Shift With Real Stakes Twelve strategy changes may sound like administrative wallpaper, but asset managers live and die by who makes the calls. T. Rowe Price is broadening portfolio-management teams across equity and fixed-income offerings while insisting that each strategy's philosophy, process, and risk limits remain intact. Fine. That is the stated...

Continue Reading
Institutions Spread AI Bets as 2027 Risks Mount Higher

Updated Category News Views 89

Money managers are not fleeing the party; they are checking the fire exits. Natixis Investment Managers surveyed 515 institutions overseeing $42.7 trillion, and their 2027 posture is pretty plain: keep taking risk, just stop pretending every risk is the same. Inflation, rates, government debt, geopolitical fracture and an AI spending boom are all tugging at portfolios at...

Continue Reading
AT&T's Dec. 8 UBS Chat Puts Stankey's Updates on Watch

Updated Category News Views 160

A Small Slot With a Big Audience A calendar entry can still matter when the man holding the microphone runs AT&T. John Stankey, AT&T chairman and chief executive, is scheduled for a fireside chat at the UBS Global Media and Communications Conference on Tuesday, Dec. 8, beginning at 8:15 a.m. Eastern time. The company says the event will be webcast live through its...

Continue Reading
Point72 Breach Puts Cyber Controls Under the Microscope

Updated Category News Views 40

Two compromised user accounts can turn a supposedly contained cyber problem into a boardroom headache in a hurry. Point72 Asset Management, the global alternative-investment firm founded by Steven A. Cohen in 2014, has reported a social-engineering incident involving accounts that were used to copy files from limited portions of its IT systems. This is not a trading-loss...

Continue Reading

Top 5 Most Recently Viewed Articles

Critical Updates for iRobot Corporation Investors and Class Action

Updated Category News Views 128

Urgent Notice for iRobot Corporation Investors Attention to all investors of iRobot Corporation (NASDAQ: IRBT)! If you have purchased securities between January 29, 2024, and March 11, 2025, it is crucial to be aware of a significant deadline approaching on September 5, 2025. This notice aims to inform and guide you through this pressing matter. Why You Should Act Now The...

Continue Reading
NeuralTrust Expands to London as AI Risks Intensify

Updated Category News Views 26

NeuralTrust's Strategic London Expansion In a world where AI agents are sprinting ahead of our security instincts, NeuralTrust makes a big play in the UK market, locking in their position with a new London office. This move isn't just about expansion—it's about tackling the tide of challenges head-on that comes with putting AI agents into the wild. London: A Hub for...

Continue Reading
Virtu Financial Reports Strong Q3 2025 Performance Highlights

Updated Category News Views 227

Virtu Financial's Q3 2025 Financial Overview As of the end of the third quarter in 2025, Virtu Financial, Inc. (NYSE: VIRT), a prominent player in the financial services sector, reported impressive results showcasing their financial strength through market challenges. Performance Metrics at a Glance During the third quarter, Virtu experienced substantial growth with a net...

Continue Reading
Understanding Super Micro Computer's Options Activity Trends

Updated Category News Views 219

Understanding Super Micro Computer's Options Activity Trends Recent movements in the options market for Super Micro Computer (SMCI) have caught the attention of investors. The influx of significant bearish activities suggests a pivotal moment could be approaching for the company. Observing the options market can provide insights into potential stock behavior, something...

Continue Reading
HUAWEI AppGallery Promises Unforgettable Gaming at Gamescom

Updated Category News Views 318

Exciting Countdown to Gamescom 2025 One Week Countdown! Prepare for an exhilarating gaming adventure as HUAWEI AppGallery gears up for an unforgettable experience at Gamescom 2025! With just one week left, gamers are invited to immerse themselves in the excitement at Booth A.040. This event promises a fantastic blend of hands-on gameplay, vibrant community activations,...

Continue Reading